About: Duration of antibiotic therapy in critically ill patients: a randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Duration of antibiotic therapy in critically ill patients: a randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Duration of antibiotic therapy in critically ill patients: a randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers
Creator	Andrade, Marcus Bergo, Rafael Borges, Isabela Carneiro, Rafael Colosimo, Enrico Martins, Larissa Nobre, Vandack Oliveira, Carolina Ravetti, Cecilia Saturnino, Saulo
Source	PMC
abstract	BACKGROUND: The rational use of antibiotics is one of the main strategies to limit the development of bacterial resistance. We therefore sought to evaluate the effectiveness of a C-reactive protein-based protocol in reducing antibiotic treatment time in critically ill patients. METHODS: A randomized, open-label, controlled clinical trial conducted in two intensive care units of a university hospital in Brazil. Critically ill infected adult patients were randomly allocated to (i) intervention to receive antibiotics guided by daily monitoring of CRP levels and (ii) control to receive antibiotics according to the best practices for rational use of antibiotics. RESULTS: One hundred thirty patients were included in the CRP (n = 64) and control (n = 66) groups. In the intention-to-treat analysis, the median duration of antibiotic therapy for the index infectious episode was 7.0 (5.0–8.8) days in the CRP and 7.0 (7.0–11.3) days in the control (p = 0.011) groups. A significant difference in the treatment time between the two groups was identified in the curve of cumulative suspension of antibiotics, with less exposure in the CRP group only for the index infection episode (p = 0.007). In the per protocol analysis, involving 59 patients in each group, the median duration of antibiotic treatment was 6.0 (5.0–8.0) days for the CRP and 7.0 (7.0–10.0) days for the control (p = 0.011) groups. There was no between-group difference regarding the total days of antibiotic exposure and antibiotic-free days. CONCLUSIONS: Daily monitoring of CRP levels may allow early interruption of antibiotic therapy in a higher proportion of patients, without an effect on total antibiotic consumption. The clinical and microbiological relevance of this finding remains to be demonstrated. TRIAL REGISTRY: ClinicalTrials.gov Identifier: NCT02987790. Registered 09 December 2016.
has issue date	2020-06-01(xsd:dateTime)
bibo:doi	10.1186/s13054-020-02946-y
has license	cc-by
sha1sum (hex)	10f3f509af838c47f9567dde96edb34416179992
schema:url	https://doi.org/10.1186/s13054-020-02946-y
resource representing a document's title	Duration of antibiotic therapy in critically ill patients: a randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers
has PubMed Central identifier	PMC7266125
schema:publication	Crit Care
resource representing a document's body	covid:10f3f509af838c47f9567dde96edb34416179992#body_text
is schema:about of	named entity 'therapy' named entity 'patients' named entity 'ANTIBIOTICS' named entity 'patients' named entity 'critically ill patients' named entity 'C-reactive protein' named entity 'bacterial resistance' named entity 'evidence-based' named entity 'critically ill patients' named entity 'diagnostic workup' named entity 'antibiotic' named entity 'bacteremia' named entity 'ICUs' named entity 'statistically significant' named entity 'empiric' named entity 'antibiotic therapy' named entity 'immunosuppression' named entity 'infection' named entity 'evolution' named entity 'microbiological' named entity 'meta-analysis' named entity 'serum levels' named entity 'antibiotics' named entity 'Armonk' named entity 'antibiotic therapy' named entity 'antibiotic' named entity 'serum levels' named entity 'serum' named entity 'antibiotic therapy' named entity 'follow-up' named entity 'study protocol' named entity 'ICUs' named entity 'evidence-based' named entity 'open-label' named entity '3.5' named entity 'clinical trial' named entity 'antibiotic treatment' named entity 'CRP' named entity 'antibiotics' named entity 'time-to-event data' named entity 'CRP' named entity 'CRP' named entity 'antibiotic' named entity 'antibiotic' named entity 'clinical practice' named entity 'adverse effects' named entity 'infection' named entity 'demographic information' named entity 'control group' named entity 'CRP' named entity 'R Foundation' named entity 'prognosis' named entity 'nosocomial infections' named entity 'CRP' named entity 'subgroup analysis' named entity 'APACHE II' named entity 'Dutch' named entity 'sepsis' named entity 'ClinicalTrials.gov' named entity 'Gram-negative bacteria' named entity 'follow-up' named entity 'Chronic Health' named entity 'antibiotic therapy' named entity 'intention to treat' named entity 'infection' named entity 'CRP' named entity 'control groups' named entity 'randomization' named entity 'CRP' named entity 'biomarker' named entity 'C-reactive protein' named entity '7.2' named entity 'antibiotic treatment' named entity 'antibiotic therapy'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software